PT1444215E - Derivados de 1,2,4-triadiazolio como moduladores do receptor de melanocortina - Google Patents

Derivados de 1,2,4-triadiazolio como moduladores do receptor de melanocortina

Info

Publication number: PT1444215E
Authority: PT; Portugal
Prior art keywords: triadiazolio; derivatives; receptor modulators; melanocortine; melanocortine receptor
Prior art date: 2001-11-08

Application number

PT02778727T

Other languages

English (en)

Inventor

Eisinger Magdalena

Louis J Fitzpatrick

Daniel H Lee

Pan Kevin

Plata-Salaman Carlos

Allen B Reitz

Virginia L Smith-Swintosky

Boyu Zhao

Original Assignee

Ortho Mcneil Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-08

Filing date

2002-11-05

Publication date

2006-10-31

2002-11-05 Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc

2006-10-31 Publication of PT1444215E publication Critical patent/PT1444215E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4018—Esters of cycloaliphatic acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Dermatology (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Birds (AREA)
Reproductive Health (AREA)
Biochemistry (AREA)
Oncology (AREA)
Gynecology & Obstetrics (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

PT02778727T 2001-11-08 2002-11-05 Derivados de 1,2,4-triadiazolio como moduladores do receptor de melanocortina PT1444215E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US33776201P	2001-11-08	2001-11-08

Publications (1)

Publication Number	Publication Date
PT1444215E true PT1444215E (pt)	2006-10-31

Family

ID=23321888

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT02778727T PT1444215E (pt)	2001-11-08	2002-11-05	Derivados de 1,2,4-triadiazolio como moduladores do receptor de melanocortina

Country Status (25)

Country	Link
US (4)	US7319107B2 (pt)
EP (1)	EP1444215B1 (pt)
JP (1)	JP4491235B2 (pt)
CN (1)	CN100422164C (pt)
AR (1)	AR037284A1 (pt)
AT (1)	ATE333449T1 (pt)
AU (1)	AU2002340372B2 (pt)
BR (1)	BR0214023A (pt)
CA (1)	CA2466145A1 (pt)
CY (1)	CY1105233T1 (pt)
DE (1)	DE60213276T2 (pt)
DK (1)	DK1444215T3 (pt)
ES (1)	ES2268108T3 (pt)
IL (2)	IL161830A0 (pt)
MX (1)	MXPA04004457A (pt)
MY (1)	MY134994A (pt)
NO (1)	NO328194B1 (pt)
NZ (1)	NZ532884A (pt)
PT (1)	PT1444215E (pt)
RS (1)	RS51199B (pt)
RU (1)	RU2323932C2 (pt)
SI (1)	SI1444215T1 (pt)
TW (1)	TWI317358B (pt)
WO (1)	WO2003040118A1 (pt)
ZA (1)	ZA200404487B (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7732451B2 (en)	2001-08-10	2010-06-08	Palatin Technologies, Inc.	Naphthalene-containing melanocortin receptor-specific small molecule
US7718802B2 (en)	2001-08-10	2010-05-18	Palatin Technologies, Inc.	Substituted melanocortin receptor-specific piperazine compounds
AU2002331064B2 (en)	2001-08-10	2007-08-23	Palatin Technologies, Inc.	Peptidomimetics of biologically active metallopeptides
US7456184B2 (en)	2003-05-01	2008-11-25	Palatin Technologies Inc.	Melanocortin receptor-specific compounds
US7655658B2 (en)	2001-08-10	2010-02-02	Palatin Technologies, Inc.	Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
WO2003040117A1 (en) *	2001-11-08	2003-05-15	Ortho-Mcneil Pharmaceutical Corporation	Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
US7319107B2 (en) *	2001-11-08	2008-01-15	Johnson & Johnson Consumer Companies, Inc.	1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
US7968548B2 (en) *	2003-05-01	2011-06-28	Palatin Technologies, Inc.	Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en)	2003-05-01	2010-06-01	Palatin Technologies, Inc.	Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en)	2003-05-01	2010-06-01	Palatin Technologies, Inc.	Substituted melanocortin receptor-specific single acyl piperazine compounds
US8460243B2 (en) *	2003-06-10	2013-06-11	Abbott Diabetes Care Inc.	Glucose measuring module and insulin pump combination
US7722536B2 (en)	2003-07-15	2010-05-25	Abbott Diabetes Care Inc.	Glucose measuring device integrated into a holster for a personal area network device
CA2557144A1 (en) *	2004-02-23	2005-09-09	Prolexys Pharmaceuticals Inc.	Non-peptidyl agents with phsp20-like activity, and uses thereof
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
US7709484B1 (en)	2004-04-19	2010-05-04	Palatin Technologies, Inc.	Substituted melanocortin receptor-specific piperazine compounds
WO2005119524A2 (en)	2004-06-04	2005-12-15	Therasense, Inc.	Diabetes care host-client architecture and data management system
US20070021433A1 (en)	2005-06-03	2007-01-25	Jian-Qiang Fan	Pharmacological chaperones for treating obesity
WO2013003594A2 (en)	2011-06-28	2013-01-03	Tearscience, Inc.	Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US20080114423A1 (en)	2006-05-15	2008-05-15	Grenon Stephen M	Apparatus for inner eyelid treatment of meibomian gland dysfunction
US7981145B2 (en)	2005-07-18	2011-07-19	Tearscience Inc.	Treatment of meibomian glands
US20090043365A1 (en) *	2005-07-18	2009-02-12	Kolis Scientific, Inc.	Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US20070060988A1 (en)	2005-07-18	2007-03-15	Grenon Stephen M	Melting meibomian gland obstructions
US7981146B2 (en) *	2006-05-15	2011-07-19	Tearscience Inc.	Inner eyelid treatment for treating meibomian gland dysfunction
US8950405B2 (en)	2006-05-15	2015-02-10	Tearscience, Inc.	Treatment of obstructive disorders of the eye or eyelid
US20070016256A1 (en) *	2005-07-18	2007-01-18	Korb Donald R	Method and apparatus for treating gland dysfunction
US7981095B2 (en) *	2005-07-18	2011-07-19	Tearscience, Inc.	Methods for treating meibomian gland dysfunction employing fluid jet
US8007524B2 (en) *	2006-05-15	2011-08-30	Tearscience, Inc.	Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8128673B2 (en) *	2006-05-15	2012-03-06	Tearscience, Inc.	System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8527313B2 (en) *	2006-05-15	2013-09-03	Sap Ag	Document instantiation triggering a business action
US7981147B2 (en) *	2006-05-15	2011-07-19	Tearscience, Inc.	Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US9314369B2 (en)	2006-05-15	2016-04-19	Tearscience, Inc.	System for inner eyelid treatment of meibomian gland dysfunction
US7976573B2 (en) *	2006-05-15	2011-07-12	Tearscience, Inc.	Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8137390B2 (en) *	2006-05-15	2012-03-20	Tearscience, Inc.	System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8128674B2 (en)	2006-05-15	2012-03-06	Tearscience, Inc.	System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7834017B2 (en)	2006-08-11	2010-11-16	Palatin Technologies, Inc.	Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
WO2008027069A1 (en) *	2006-08-21	2008-03-06	Tearscience, Inc.	Method and apparatus for treating meibomian gland dysfunction employing fluid
USD613408S1 (en)	2008-02-06	2010-04-06	Tearscience, Inc.	Eye treatment head gear
USD617443S1 (en)	2008-02-06	2010-06-08	Tearscience, Inc.	Eye treatment goggles
ES2453640T3 (es)	2008-02-21	2014-04-08	Janssen Pharmaceutica N.V.	Métodos para el tratamiento de desordenes dermatológicos
US8377925B2 (en)	2008-02-29	2013-02-19	Mimetica Pty Ltd	Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
US8008291B2 (en) *	2008-02-29	2011-08-30	Mimetica Pty Ltd	3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
US8343958B2 (en)	2008-02-29	2013-01-01	Mimetica Pty Ltd	3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists
EP2358200A4 (en)	2008-11-17	2012-05-16	Merck Sharp & Dohme	SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES
US8877776B2 (en)	2009-01-16	2014-11-04	Exelixis, Inc.	(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
BRPI1013853A2 (pt) *	2009-04-24	2019-09-24	Janssen Pharmaceuticals Inc	composições tópicas estáveis de derivados de 1,2,4-tiadiazol
US20120220567A1 (en)	2009-07-23	2012-08-30	Shipps Jr Gerald W	Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en)	2009-07-23	2011-01-27	Schering Corporation	Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
ES2360783B1 (es) *	2009-10-02	2012-07-04	Consejo Superior De Investigaciones Científicas (Csic)	1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas
USD638128S1 (en)	2009-10-06	2011-05-17	Tearscience, Inc.	Ocular device design
WO2011137024A1 (en)	2010-04-26	2011-11-03	Merck Sharp & Dohme Corp.	Novel spiropiperidine prolylcarboxypeptidase inhibitors
EP2568812B1 (en)	2010-05-11	2016-10-26	Merck Sharp & Dohme Corp.	Novel prolylcarboxypeptidase inhibitors
US9006268B2 (en)	2010-06-11	2015-04-14	Merck Sharp & Dohme Corp.	Prolylcarboxypeptidase inhibitors
EP2628734A4 (en) *	2010-10-15	2014-04-23	Federalnoe G Bydzhetnoe Uchrezhdenie Nauki Inst Fiziol Aktivnikh Veschestv Rossiiskoi Akademii Nauk	DERIVATIVES OF 5-AMINO - [1,2,4] THIADIAZOLE
US9018395B2 (en)	2011-01-27	2015-04-28	Université de Montréal	Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
US10136845B2 (en)	2011-02-28	2018-11-27	Abbott Diabetes Care Inc.	Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
ES2868231T3 (es) *	2011-03-07	2021-10-21	Amgen Europe Gmbh	Métodos de tratamiento de enfermedades usando compuestos de isoindolina
WO2013102047A1 (en)	2011-12-29	2013-07-04	Rhythm Pharmaceuticals, Inc.	Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
US10842670B2 (en)	2012-08-22	2020-11-24	Johnson & Johnson Vision Care, Inc.	Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
EP3424558B1 (en)	2013-04-30	2020-07-22	Alcon Inc.	Systems for the treatment of eye conditions
US9763827B2 (en)	2013-04-30	2017-09-19	Tear Film Innovations, Inc.	Systems and methods for the treatment of eye conditions
US10265348B2 (en)	2014-10-31	2019-04-23	Lipotec S.A.U.	Cosmetic and/or pharmaceutical composition containing a bacterial extracellular product from pseudoalteromonas antarctica, and use thereof
FI3356386T3 (fi)	2015-09-30	2024-05-16	Rhythm Pharmaceuticals Inc	Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä
US10974063B2 (en)	2016-06-30	2021-04-13	Alcon Inc.	Light therapy for eyelash growth
EP3773897A1 (en)	2018-04-06	2021-02-17	Rhythm Pharmaceuticals, Inc.	Compositions for treating kidney disease
CN115381955B (zh) *	2021-05-24	2024-05-17	中国科学技术大学	黑皮质素受体mc5r的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE131373C (pt)
DD131373A1 (de)	1977-06-17	1978-06-21	Juergen Liebscher	Verfahren zur herstellung von 2,3-disubstituierten 5-dialkylamino-1,2,4-thiadiazoliumsalzen
JPS6011481A (ja)	1983-06-30	1985-01-21	Nippon Soda Co Ltd	１，２，４−チアジアゾ−ル系誘導体及び農園芸用殺菌剤
JPH02173165A (ja)	1988-12-27	1990-07-04	Nippon Soda Co Ltd	防汚剤
DK0805153T3 (da) *	1996-04-30	2002-03-18	Pfizer	Hidtil ukendte muskarine receptoragonister
US20020103194A1 (en) *	1997-04-30	2002-08-01	Anabella Villalobos	Novel muscarinic receptor agonists
EP1076649A4 (en)	1998-04-28	2010-06-02	Trega Biosciences Inc	ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
CN1111523C (zh)	1998-04-29	2003-06-18	阿克西瓦有限公司	催化制备取代的联吡啶衍生物的方法
JP2002517444A (ja)	1998-06-11	2002-06-18	メルクエンドカムパニーインコーポレーテッド	メラノコルチン受容体作動薬としてのスピロピペリジン誘導体
US6294534B1 (en)	1998-06-11	2001-09-25	Merck & Co., Inc.	Spiropiperidine derivatives as melanocortin receptor agonists
AU1324300A (en)	1998-10-26	2000-05-15	Vertex Pharmaceuticals Incorporated	Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
AU2001228681A1 (en)	2000-01-28	2001-08-07	Melacure Therapeutics Ab	Novel aromatic amines and amides acting on the melanocortin receptors
AU4928101A (en) *	2000-03-23	2001-10-03	Merck & Co Inc	Spiropiperidine derivatives as melanocortin receptor agonists
US6728804B1 (en)	2000-10-27	2004-04-27	Emware, Inc.	Remotely reprogrammable communications adapter for providing access to an electronic device
US7319107B2 (en) *	2001-11-08	2008-01-15	Johnson & Johnson Consumer Companies, Inc.	1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
WO2003040117A1 (en) *	2001-11-08	2003-05-15	Ortho-Mcneil Pharmaceutical Corporation	Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
US7435429B2 (en) *	2002-02-07	2008-10-14	Trustees Of Columbia University In The City Of New York	Zinc salt compositions for the prevention of dermal and mucosal irritation
ES2453640T3 (es) *	2008-02-21	2014-04-08	Janssen Pharmaceutica N.V.	Métodos para el tratamiento de desordenes dermatológicos
BRPI1013853A2 (pt) *	2009-04-24	2019-09-24	Janssen Pharmaceuticals Inc	composições tópicas estáveis de derivados de 1,2,4-tiadiazol

2002
- 2002-11-04 US US10/287,096 patent/US7319107B2/en not_active Expired - Fee Related
- 2002-11-05 EP EP02778727A patent/EP1444215B1/en not_active Expired - Lifetime
- 2002-11-05 NZ NZ532884A patent/NZ532884A/en not_active IP Right Cessation
- 2002-11-05 SI SI200230407T patent/SI1444215T1/sl unknown
- 2002-11-05 RS YUP-396/04A patent/RS51199B/sr unknown
- 2002-11-05 RU RU2004114208/04A patent/RU2323932C2/ru not_active IP Right Cessation
- 2002-11-05 BR BR0214023-3A patent/BR0214023A/pt active Search and Examination
- 2002-11-05 AU AU2002340372A patent/AU2002340372B2/en not_active Ceased
- 2002-11-05 PT PT02778727T patent/PT1444215E/pt unknown
- 2002-11-05 CN CNB028268989A patent/CN100422164C/zh not_active Expired - Fee Related
- 2002-11-05 DK DK02778727T patent/DK1444215T3/da active
- 2002-11-05 ES ES02778727T patent/ES2268108T3/es not_active Expired - Lifetime
- 2002-11-05 IL IL16183002A patent/IL161830A0/xx unknown
- 2002-11-05 WO PCT/US2002/035365 patent/WO2003040118A1/en active IP Right Grant
- 2002-11-05 DE DE60213276T patent/DE60213276T2/de not_active Expired - Lifetime
- 2002-11-05 AT AT02778727T patent/ATE333449T1/de active
- 2002-11-05 JP JP2003542164A patent/JP4491235B2/ja not_active Expired - Fee Related
- 2002-11-05 MX MXPA04004457A patent/MXPA04004457A/es active IP Right Grant
- 2002-11-05 CA CA002466145A patent/CA2466145A1/en not_active Abandoned
- 2002-11-07 AR ARP020104271A patent/AR037284A1/es not_active Application Discontinuation
- 2002-11-08 TW TW091133318A patent/TWI317358B/zh not_active IP Right Cessation
- 2002-11-08 MY MYPI20024180A patent/MY134994A/en unknown
2004
- 2004-05-06 IL IL161830A patent/IL161830A/en not_active IP Right Cessation
- 2004-06-07 ZA ZA200404487A patent/ZA200404487B/en unknown
- 2004-06-07 NO NO20042373A patent/NO328194B1/no not_active IP Right Cessation
2005
- 2005-09-27 US US11/236,097 patent/US20060030604A1/en not_active Abandoned
2006
- 2006-09-15 CY CY20061101325T patent/CY1105233T1/el unknown
2008
- 2008-08-05 US US12/221,900 patent/US7786311B2/en not_active Expired - Fee Related
2010
- 2010-07-13 US US12/835,220 patent/US8501791B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20060030604A1 (en)	2006-02-09
MXPA04004457A (es)	2005-06-08
ATE333449T1 (de)	2006-08-15
AR037284A1 (es)	2004-11-03
TWI317358B (en)	2009-11-21
TW200303310A (en)	2003-09-01
CA2466145A1 (en)	2003-05-15
WO2003040118A1 (en)	2003-05-15
US7319107B2 (en)	2008-01-15
DK1444215T3 (da)	2006-11-06
CN100422164C (zh)	2008-10-01
RU2323932C2 (ru)	2008-05-10
RU2004114208A (ru)	2005-09-10
CY1105233T1 (el)	2010-03-03
US20090203751A1 (en)	2009-08-13
DE60213276D1 (de)	2006-08-31
US7786311B2 (en)	2010-08-31
ZA200404487B (en)	2006-08-30
JP4491235B2 (ja)	2010-06-30
US20100280079A1 (en)	2010-11-04
EP1444215A1 (en)	2004-08-11
US20030162819A1 (en)	2003-08-28
SI1444215T1 (sl)	2006-12-31
RS51199B (sr)	2010-12-31
BR0214023A (pt)	2004-11-23
DE60213276T2 (de)	2007-07-19
MY134994A (en)	2008-01-31
AU2002340372B2 (en)	2008-12-11
RS39604A (en)	2006-10-27
CN1612869A (zh)	2005-05-04
ES2268108T3 (es)	2007-03-16
JP2005511606A (ja)	2005-04-28
NZ532884A (en)	2006-06-30
IL161830A (en)	2010-11-30
NO328194B1 (no)	2010-01-04
NO20042373L (no)	2004-06-07
US8501791B2 (en)	2013-08-06
IL161830A0 (en)	2005-11-20
EP1444215B1 (en)	2006-07-19

Publication	Publication Date	Title
PT1444215E (pt)	2006-10-31	Derivados de 1,2,4-triadiazolio como moduladores do receptor de melanocortina
PT1177185E (pt)	2005-08-31	Derivados de 4, 5, 6, 7-tetra-hidroindazole como agentes antitumorais
PT1379511E (pt)	2005-10-31	Derivados de di-hidro-benzo[b] [1,4] diazepin-2-ona como antagonistas ii de r2glum
DK1446394T3 (da)	2007-03-12	Hidtil ukendte 1,2,4-thiadiazolderivater som melanocortinreceptormodulatorer
PT1404667E (pt)	2006-07-31	Derivados de piperidina uteis como moduladores da actividade do receptor de quimiocina
DE50210707D1 (de)	2007-09-27	Substituierte 2-pyridin-cyclohexan-1,4-diaminderivate
PT1406628E (pt)	2006-06-30	Derivados de tera-hidroquinolina
ATE293962T1 (de)	2005-05-15	Adenosin-rezeptor modulatoren
PT1287001E (pt)	2004-12-31	Derivados de tiofeno uteis como agentes anticancerigenos
DE60225563D1 (de)	2008-04-24	4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
PT1218378E (pt)	2003-09-30	Derivados de terc-butil-(7-metil-imidazo-¬1,2-a\|-piridin-3-il)-amina
PT1379522E (pt)	2005-05-31	Derivados de di-hidro-benzo[b] [1,4] diazepina-2-ona como antagonistas i do r2glum
DE602004006169D1 (de)	2007-06-06	Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate
PT1198453E (pt)	2003-08-29	Derivados de n-(indolcarbonil)-piperazina como ligandos do receptor 5-ht2a
ATE283857T1 (de)	2004-12-15	Imidazo(1,5-aöpyrimido)5,4-döbenz azepinderivate als gaba-a-rezeptormodulatoren
BR0202206B1 (pt)	2013-02-05	estrutura de suspensço.
NO20013997L (no)	2001-10-17	Reseptoranalyse
DE602004014772D1 (de)	2008-08-14	Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
PT1389213E (pt)	2006-07-31	Formulacoes de 3,7-diazabiciclo 3,3,1¿ como compostos antiarritmicos
PT1171419E (pt)	2005-04-29	Derivados de bifenilo como antagonistas do receptor da neuroquinina-1
PT1467998E (pt)	2006-08-31	Heterocompostos tetraciclicos como moduladores do receptor do estrogenio
DE60237271D1 (de)	2010-09-23	Tintensatz
DE50010538D1 (de)	2005-07-21	Mehrkanal-Tropfengenerator
PT1317430E (pt)	2005-09-30	Derivados de (2-azabiciclo[2.2.1]hepta-7-il)-metanol como agonistas do receptor nocotinico de acetilcolina
NO20021295L (no)	2002-05-14	Nikotinsyreacetylcholin-reseptor